Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Coherus Oncology (CHRS) over the last 7 years, with Q3 2025 value amounting to $3.7 million.

  • Coherus Oncology's Cost of Revenue rose 3635.03% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 3401.77%. This contributed to the annual value of $117.6 million for FY2024, which is 2606.36% down from last year.
  • Latest data reveals that Coherus Oncology reported Cost of Revenue of $3.7 million as of Q3 2025, which was up 3635.03% from $3.4 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Cost of Revenue high stood at $111.6 million for Q4 2024, and its period low was $1.4 million during Q1 2024.
  • Moreover, its 5-year median value for Cost of Revenue was $12.1 million (2021), whereas its average is $21.8 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 49545.84% in 2023, then plummeted by 9271.97% in 2024.
  • Quarter analysis of 5 years shows Coherus Oncology's Cost of Revenue stood at $12.1 million in 2021, then grew by 17.33% to $14.2 million in 2022, then soared by 495.46% to $84.6 million in 2023, then soared by 31.94% to $111.6 million in 2024, then tumbled by 96.67% to $3.7 million in 2025.
  • Its Cost of Revenue was $3.7 million in Q3 2025, compared to $3.4 million in Q2 2025 and $2.7 million in Q1 2025.